RxDoctor Payments Data

Steven Hutchins

Advanced Heart Failure and Transplant Cardiology · Little Rock, ARNPI 1942315379

Payments from drug & device makers

$2,250in general payments, 2019–2025

Across 125 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$687
  • Alnylam Pharmaceuticals Inc.$273
  • Abbott$203
  • Boehringer Ingelheim$169
  • United Therapeutics Corporation$156
  • Actelion Pharmaceuticals US, Inc.$152
  • plus $610 from 17 others

What the payments were for

  • Food & beverage$2,23299%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$39,079
Medicare patients
288
Services billed
963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis28$785,459
Orenitram ErTreprostinil Diolamine13$318,476
EntrestoSacubitril/Valsartan352$310,515
JardianceEmpagliflozin163$116,092
EliquisApixaban118$98,746
XareltoRivaroxaban58$44,506
Repatha SureclickEvolocumab52$32,790
Sirolimus52$31,824
CorlanorIvabradine Hcl22$16,591
Mycophenolate Mofetil62$10,543
LinzessLinaclotide11$7,448
Tacrolimus66$7,181
Potassium Chloride147$3,525
Torsemide183$3,301
Metoprolol Succinate250$3,063

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$80$884,205146 claims
NovartisEntresto$687$310,515352 claims
Boehringer IngelheimJardiance$169$116,092163 claims
Johnson & JohnsonXarelto$12$44,50658 claims
AmgenCorlanor$63$16,59122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Arkansason file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Little Rock

Where these figures come from

Is this you, or does something look wrong? →